Skip to main navigation

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Financials
- SEC Filings
- IRS Form 8937
Stock
Resources

News Releases

Year

28 Nov '23

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

22 Nov '23

Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

09 Nov '23

Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

31 Oct '23

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

25 Oct '23

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

05 Sep '23

Carisma Therapeutics to Present at Upcoming Investor Conferences

01 Sep '23

Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

24 Aug '23

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

10 Aug '23

Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

28 Jun '23

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 32

Site - Investor Tools

Print Page
Email Alerts
RSS Feeds
IR Contact

Request Email Alerts

© 2023 Carisma Therapeutics Inc. All rights reserved.